mTOR: on target for novel therapeutic strategies in the nervous system

Chong, 2010, Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders, Oxid. Med. Cell. Longev., 3, 374, 10.4161/oxim.3.6.14787 Brown, 1994, A mammalian protein targeted by G1-arresting rapamycin–receptor complex, Nature, 369, 756, 10.1038/369756a0 Heitman, 1991, Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast, Science, 253, 905, 10.1126/science.1715094 Chong, 2012, Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin, Prog. Neurobiol., 99, 128, 10.1016/j.pneurobio.2012.08.001 Takahashi, 2000, Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro, Genes Cells, 5, 765, 10.1046/j.1365-2443.2000.00365.x Benjamin, 2011, Rapamycin passes the torch: a new generation of mTOR inhibitors, Nat. Rev. Drug Discov., 10, 868, 10.1038/nrd3531 Acosta-Jaquez, 2009, Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth, Mol. Cell. Biol., 29, 4308, 10.1128/MCB.01665-08 Chiang, 2005, Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase, J. Biol. Chem., 280, 25485, 10.1074/jbc.M501707200 Reynolds, 2002, Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load, J. Biol. Chem., 277, 17657, 10.1074/jbc.M201142200 Soliman, 2010, mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action, J. Biol. Chem., 285, 7866, 10.1074/jbc.M109.096222 Wang, 2009, Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR, J. Biol. Chem., 284, 14693, 10.1074/jbc.C109.002907 Wang, 2012, Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway, Cell. Signal., 24, 17, 10.1016/j.cellsig.2011.08.010 Chen, 2003, LST8 negatively regulates amino acid biosynthesis as a component of the TOR pathway, J. Cell Biol., 161, 333, 10.1083/jcb.200210141 Kim, 2003, GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR, Mol. Cell, 11, 895, 10.1016/S1097-2765(03)00114-X Guertin, 2006, Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1, Dev. Cell, 11, 859, 10.1016/j.devcel.2006.10.007 Peterson, 2009, DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival, Cell, 137, 873, 10.1016/j.cell.2009.03.046 Zhao, 2011, DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy, Mol. Cell, 44, 304, 10.1016/j.molcel.2011.08.029 Sarbassov, 2005, Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex, Science, 307, 1098, 10.1126/science.1106148 Chen, 2011, The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2, J. Biol. Chem., 286, 40386, 10.1074/jbc.M111.282590 Pearce, 2011, Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney, Biochem. J., 436, 169, 10.1042/BJ20102103 Gingras, 1998, 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway, Genes Dev., 12, 502, 10.1101/gad.12.4.502 Lenz, 2005, Glutamatergic regulation of the p70S6 kinase in primary mouse neurons, J. Biol. Chem., 280, 38121, 10.1074/jbc.C500363200 Cota, 2006, Hypothalamic mTOR signaling regulates food intake, Science, 312, 927, 10.1126/science.1124147 Sarbassov, 2004, Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton, Curr. Biol., 14, 1296, 10.1016/j.cub.2004.06.054 Gulhati, 2011, mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways, Cancer Res., 71, 3246, 10.1158/0008-5472.CAN-10-4058 Hernandez-Negrete, 2007, P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration, J. Biol. Chem., 282, 23708, 10.1074/jbc.M703771200 Cai, 2006, Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning, J. Cell Biol., 173, 279, 10.1083/jcb.200507119 Huang, 2008, The TSC1–TSC2 complex is required for proper activation of mTOR complex 2, Mol. Cell. Biol., 28, 4104, 10.1128/MCB.00289-08 Inoki, 2003, TSC2 mediates cellular energy response to control cell growth and survival, Cell, 115, 577, 10.1016/S0092-8674(03)00929-2 DeYoung, 2008, Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling, Genes Dev., 22, 239, 10.1101/gad.1617608 Murakami, 2004, mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells, Mol. Cell. Biol., 24, 6710, 10.1128/MCB.24.15.6710-6718.2004 Gangloff, 2004, Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development, Mol. Cell. Biol., 24, 9508, 10.1128/MCB.24.21.9508-9516.2004 Zhou, 2009, mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells, Proc. Natl. Acad. Sci. U.S.A., 106, 7840, 10.1073/pnas.0901854106 Iriuchishima, 2011, Ex vivo maintenance of hematopoietic stem cells by quiescence induction through Fbxw7α overexpression, Blood, 117, 2373, 10.1182/blood-2010-07-294801 Easley, 2010, mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells, Cell. Reprogramm., 12, 263, 10.1089/cell.2010.0011 Han, 2008, Mammalian target of rapamycin (mTOR) is involved in the neuronal differentiation of neural progenitors induced by insulin, Mol. Cell. Neurosci., 39, 118, 10.1016/j.mcn.2008.06.003 Malagelada, 2011, RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration, J. Neurosci., 31, 3186, 10.1523/JNEUROSCI.4011-10.2011 Magri, 2011, Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions, Cell Stem Cell, 9, 447, 10.1016/j.stem.2011.09.008 Maiese, 2005, New avenues of exploration for erythropoietin, JAMA, 293, 90, 10.1001/jama.293.1.90 Shang, 2011, Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia, Curr. Neurovasc. Res., 8, 270, 10.2174/156720211798120990 Kim, 2012, Erythropoietin mediated bone formation is regulated by mTOR signaling, J. Cell. Biochem., 113, 220, 10.1002/jcb.23347 Miriuka, 2006, mTOR inhibition induces endothelial progenitor cell death, Am. J. Transplant., 6, 2069, 10.1111/j.1600-6143.2006.01433.x Sato, 2010, Regulation of neural stem/progenitor cell maintenance by PI3K and mTOR, Neurosci. Lett., 470, 115, 10.1016/j.neulet.2009.12.067 Maiese, 2008, The Wnt signaling pathway: aging gracefully as a protectionist?, Pharmacol. Ther., 118, 58, 10.1016/j.pharmthera.2008.01.004 Inoki, 2006, TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth, Cell, 126, 955, 10.1016/j.cell.2006.06.055 Huang, 2009, Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice, J. Clin. Invest., 119, 3519 Chong, 2005, Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease, Prog. Neurobiol., 75, 207, 10.1016/j.pneurobio.2005.02.004 Zengi, 2011, Increased oxidative DNA damage in lean normoglycemic offspring of type 2 diabetic patients, Exp. Clin. Endocrinol. Diabetes, 119, 467, 10.1055/s-0031-1275289 Vendelbo, 2011, Mitochondrial longevity pathways, Biochim. Biophys. Acta, 1813, 634, 10.1016/j.bbamcr.2011.01.029 Tupe, 2011, Dietary nicotinic acid supplementation improves hepatic zinc uptake and offers hepatoprotection against oxidative damage, Br. J. Nutr., 25, 1 Maiese, 2010, Oxidative stress: biomarkers and novel therapeutic pathways, Exp. Gerontol., 45, 217, 10.1016/j.exger.2010.01.004 Maiese, 2012, Targeting disease through novel pathways of apoptosis and autophagy, Expert Opin. Ther. Targets, 16, 1203, 10.1517/14728222.2012.719499 Louneva, 2008, Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease, Am. J. Pathol., 173, 1488, 10.2353/ajpath.2008.080434 Tatton, 2000, Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease, Exp. Neurol., 166, 29, 10.1006/exnr.2000.7489 Canu, 2005, Role of the autophagic-lysosomal system on low potassium-induced apoptosis in cultured cerebellar granule cells, J. Neurochem., 92, 1228, 10.1111/j.1471-4159.2004.02956.x Qin, 2010, Autophagy was activated in injured astrocytes and mildly decreased cell survival following glucose and oxygen deprivation and focal cerebral ischemia, Autophagy, 6, 738, 10.4161/auto.6.6.12573 Wang, 2011, Severe global cerebral ischemia-induced programmed necrosis of hippocampal CA1 neurons in rat is prevented by 3-methyladenine: a widely used inhibitor of autophagy, J. Neuropathol. Exp. Neurol., 70, 314, 10.1097/NEN.0b013e31821352bd Baba, 2009, Autophagy-mediated stress response in motor neuron after transient ischemia in rabbits, J. Vasc. Surg., 50, 381, 10.1016/j.jvs.2009.03.042 Spencer, 2009, Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases, J. Neurosci., 29, 13578, 10.1523/JNEUROSCI.4390-09.2009 Spilman, 2010, Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease, PLoS ONE, 5, e9979, 10.1371/journal.pone.0009979 Jeong, 2012, Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity, Neurosci. Res., 73, 99, 10.1016/j.neures.2012.03.005 Chen, 2010, Hydrogen peroxide inhibits mTOR signaling by activation of AMPKα leading to apoptosis of neuronal cells, Lab. Invest., 90, 762, 10.1038/labinvest.2010.36 Wu, 2004, Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner, J. Biol. Chem., 279, 9167, 10.1074/jbc.M312397200 Shang, 2012, Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL, Aging (Albany NY), 4, 187, 10.18632/aging.100440 Chong, 2007, The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3β and nuclear factor-κB to foster endogenous microglial cell protection, Int. J. Mol. Med., 19, 263 Pastor, 2009, mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia, J. Biol. Chem., 284, 22067, 10.1074/jbc.M109.033100 Choi, 2010, A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death, J. Neurochem., 112, 366, 10.1111/j.1471-4159.2009.06463.x Chong, 2012, PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection, PLoS ONE, 7, e45456, 10.1371/journal.pone.0045456 Nascimento, 2010, Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1, Cell. Signal., 22, 961, 10.1016/j.cellsig.2010.02.002 Carayol, 2010, Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells, Proc. Natl. Acad. Sci. U.S.A., 107, 12469, 10.1073/pnas.1005114107 Luo, 2010, Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL, Cell Death Differ., 17, 268, 10.1038/cdd.2009.121 Wang, 2012, WISP1 (CCN4) autoregulates its expression and nuclear trafficking of beta-catenin during oxidant stress with limited effects upon neuronal autophagy, Curr. Neurovasc. Res., 9, 89, 10.2174/156720212800410858 Le, 2010, Dasatinib induces autophagic cell death in human ovarian cancer, Cancer, 116, 4980, 10.1002/cncr.25426 Salminen, 2011, AMP-activated protein kinase: a potential player in Alzheimer's disease, J. Neurochem., 118, 460, 10.1111/j.1471-4159.2011.07331.x Yu, 2010, Termination of autophagy and reformation of lysosomes regulated by mTOR, Nature, 465, 942, 10.1038/nature09076 Rong, 2011, Spinster is required for autophagic lysosome reformation and mTOR reactivation following starvation, Proc. Natl. Acad. Sci. U.S.A., 108, 7826, 10.1073/pnas.1013800108 Jung, 2009, ULK–Atg13–FIP200 complexes mediate mTOR signaling to the autophagy machinery, Mol. Biol. Cell, 20, 1992, 10.1091/mbc.E08-12-1249 Hosokawa, 2009, Atg101, a novel mammalian autophagy protein interacting with Atg13, Autophagy, 5, 973, 10.4161/auto.5.7.9296 Slipczuk, 2009, BDNF activates mTOR to regulate GluR1 expression required for memory formation, PLoS ONE, 4, e6007, 10.1371/journal.pone.0006007 Griffin, 2005, Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology, J. Neurochem., 93, 105, 10.1111/j.1471-4159.2004.02949.x An, 2003, Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease, Am. J. Pathol., 163, 591, 10.1016/S0002-9440(10)63687-5 Paccalin, 2006, Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease, Dement. Geriatr. Cogn. Disord., 22, 320, 10.1159/000095562 Ma, 2010, Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease, PLoS ONE, 5, e12845, 10.1371/journal.pone.0012845 Lafay-Chebassier, 2005, mTOR/p70S6k signalling alteration by Aβ exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease, J. Neurochem., 94, 215, 10.1111/j.1471-4159.2005.03187.x Chano, 2007, RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases, Brain Res., 1168, 97, 10.1016/j.brainres.2007.06.075 Imai, 2008, Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila, EMBO J., 27, 2432, 10.1038/emboj.2008.163 Tain, 2009, Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss, Nat. Neurosci., 12, 1129, 10.1038/nn.2372 Malagelada, 2006, RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation, J. Neurosci., 26, 9996, 10.1523/JNEUROSCI.3292-06.2006 Crews, 2010, Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy, PLoS ONE, 5, e9313, 10.1371/journal.pone.0009313 Santini, 2009, Inhibition of mTOR signaling in Parkinson's disease prevents l-DOPA-induced dyskinesia, Sci. Signal., 2, ra36, 10.1126/scisignal.2000308 Berger, 2006, Rapamycin alleviates toxicity of different aggregate-prone proteins, Hum. Mol. Genet., 15, 433, 10.1093/hmg/ddi458 Ravikumar, 2004, Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease, Nat. Genet., 36, 585, 10.1038/ng1362 Floto, 2007, Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages, Autophagy, 3, 620, 10.4161/auto.4898 Roscic, 2011, Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model, J. Neurochem., 119, 398, 10.1111/j.1471-4159.2011.07435.x Fox, 2010, The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease, Mol. Neurodegener., 5, 26, 10.1186/1750-1326-5-26 Hyrskyluoto, 2012, GADD34 mediates cytoprotective autophagy in mutant huntingtin expressing cells via the mTOR pathway, Exp. Cell Res., 318, 33, 10.1016/j.yexcr.2011.08.020 Holmes, 2007, Tuberous sclerosis complex and epilepsy: recent developments and future challenges, Epilepsia, 48, 617, 10.1111/j.1528-1167.2007.01035.x Jozwiak, 2009, Fibroblasts from normal skin of a tuberous sclerosis patient show upregulation of mTOR pathway, Am. J. Dermatopathol., 31, 68, 10.1097/DAD.0b013e3181882c09 Waltereit, 2006, Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis, J. Neurochem., 96, 407, 10.1111/j.1471-4159.2005.03538.x Zeng, 2008, Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex, Ann. Neurol., 63, 444, 10.1002/ana.21331 Buckmaster, 2009, Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy, J. Neurosci., 29, 8259, 10.1523/JNEUROSCI.4179-08.2009 Zeng, 2009, The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy, J. Neurosci., 29, 6964, 10.1523/JNEUROSCI.0066-09.2009 Curran, 2012, Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex, Paediatr. Drugs, 14, 51, 10.2165/11207730-000000000-00000 Krueger, 2010, Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis, N. Engl. J. Med., 363, 1801, 10.1056/NEJMoa1001671 Pavel, 2011, Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study, Lancet, 378, 2005, 10.1016/S0140-6736(11)61742-X Jin, 2009, Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer, J. Clin. Endocrinol. Metab., 94, 4107, 10.1210/jc.2009-0662 Gulhati, 2012, Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA, Carcinogenesis, 33, 1782, 10.1093/carcin/bgs203 Mi, 2009, Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model, J. Genet. Genomics, 36, 355, 10.1016/S1673-8527(08)60124-1 Fokas, 2012, NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity, Radiat. Oncol., 7, 48, 10.1186/1748-717X-7-48 Barrett, 2012, Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies, Paediatr. Drugs, 14, 299 Grzybowska-Izydorczyk, 2012, mTOR kinase inhibitors as a treatment strategy in hematological malignancies, Future Med. Chem., 4, 487, 10.4155/fmc.12.14 Majumder, 2011, Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits, PLoS ONE, 6, e25416, 10.1371/journal.pone.0025416